Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Karimi

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Blood|January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialJoshua D Brody, Judit Jørgensen, David Belada, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
The Laryngoscope|May 6, 2025
Transcriptomic Features of Recurrence Rates in Idiopathic Subglottic StenosisShengjie Ying, Peter Y F Zeng, Kevin Fung, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Epilepsy & Behavior : E&B|August 7, 2022
Clinical MRI morphological analysis of functional seizures compared to seizure-naïve and psychiatric controlsWesley T Kerr, Hiroyuki Tatekawa, John K Lee, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Journal of the Neurological Sciences|July 3, 2021
A minority of patients with functional seizures have abnormalities on neuroimagingWesley T Kerr, John K Lee, Amir H Karimi, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 15, 2019
Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas DiseaseUriel Ortega-Rodriguez, Susana Portillo, Roger A Ashmus, et al.
Seizure|March 19, 2019
Reliability of reported peri-ictal behavior to identify psychogenic nonepileptic seizuresWesley T Kerr, Andrea M Chau, Emily A Janio, et al.
Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Blood|January 10, 2025
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialJoshua D Brody, Judit Jørgensen, David Belada, et al.
Blood Advances|February 20, 2020
A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemiaKirk E Cahill, Yasmin H Karimi, Theodore G Karrison, et al.
The Laryngoscope|May 6, 2025
Transcriptomic Features of Recurrence Rates in Idiopathic Subglottic StenosisShengjie Ying, Peter Y F Zeng, Kevin Fung, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Epilepsy & Behavior : E&B|August 7, 2022
Clinical MRI morphological analysis of functional seizures compared to seizure-naïve and psychiatric controlsWesley T Kerr, Hiroyuki Tatekawa, John K Lee, et al.
Haematologica|March 5, 2026
Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trialPau Abrisqueta, Yasmin H Karimi, Daniel Morillo, et al.
Journal of the Neurological Sciences|July 3, 2021
A minority of patients with functional seizures have abnormalities on neuroimagingWesley T Kerr, John K Lee, Amir H Karimi, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 15, 2019
Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcomes of Chagas DiseaseUriel Ortega-Rodriguez, Susana Portillo, Roger A Ashmus, et al.
Seizure|March 19, 2019
Reliability of reported peri-ictal behavior to identify psychogenic nonepileptic seizuresWesley T Kerr, Andrea M Chau, Emily A Janio, et al.
Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.
Pageof 16